Genmab announces share buy-back transactions

COPENHAGEN - Genmab (NASDAQ:GMAB) A/S, the Danish biotechnology company, has reported transactions made under its share buy-back program in a filing with the U.S. Securities and Exchange Commission (SEC). The disclosure, submitted today, details the company’s latest buy-back activities, which took place from May 12 to May 16, 2025.

The buy-back program is part of Genmab’s ongoing strategy to adjust its capital structure and return value to shareholders. Under this initiative, the company repurchases its own shares in the open market. The transactions are conducted in accordance with the authorization granted by the company’s shareholders and are subject to regulatory requirements.

The specific details of the shares bought back during the specified period were not disclosed in the summary provided. However, the filing indicates that the information is incorporated by reference into Genmab’s registration statements on Form S-8, suggesting that the transactions could relate to employee incentive programs.

The report is filed under Form 6-K, which is used by foreign private issuers to furnish periodic and other reports to the SEC. This form is a requirement for Genmab as it is listed on the U.S. stock exchange and must comply with American regulatory standards.

As per the SEC filing, the report on Form 6-K will be deemed to be incorporated by reference into Genmab’s existing registration statements, and will be a part of the official record from the date of filing, to the extent not superseded by documents or reports subsequently filed or furnished.

This information is based on a press release statement and is intended to provide shareholders and potential investors with an update on the company’s use of its share buy-back program. Further details of the buy-back transactions can be expected to be provided in subsequent filings or company announcements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.